Edition:
India

Leap Therapeutics Inc (LPTX.OQ)

LPTX.OQ on NASDAQ Stock Exchange Global Market

8.62USD
20 Jun 2018
Change (% chg)

$0.33 (+3.98%)
Prev Close
$8.29
Open
$8.29
Day's High
$9.08
Day's Low
$8.20
Volume
23,743
Avg. Vol
19,938
52-wk High
$10.25
52-wk Low
$4.94

Chart for

About

Leap Therapeutics, Inc., formerly HealthCare Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-re... (more)

Overall

Beta: --
Market Cap(Mil.): $50.10
Shares Outstanding(Mil.): 9.40
Dividend: --
Yield (%): --

Financials

BRIEF-Leap Therapeutics Files For Mixed Shelf Of Up To $100 Mln

* LEAP THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $100 MILLION - SEC FILING ‍​ Source text : (http://bit.ly/2I0IyH4) Further company coverage:

03 Mar 2018

BRIEF-Leap Therapeutics Reports Qtrly Loss Per Share Of $0.65

* LEAP THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND ANNOUNCES DATE OF ITS ANNUAL MEETING OF STOCKHOLDERS

23 Feb 2018

BRIEF-Leap Therapeutics Announces First Patient Dosed With TRX518 Combination Therapy

* LEAP THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED WITH TRX518 COMBINATION THERAPY IN ADVANCED SOLID TUMORS TRIAL Source text for Eikon: Further company coverage:

16 Jan 2018

Earnings vs. Estimates